MDCLF (Medincell) Other Income (Expense): $-6.26 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MDCLF Medincell SA MDCLF
77 GF Score
Price $34.39
GF Value $27.51
! 5 Warning Signs
View Full Analysis

What is Medincell Other Income (Expense)?

Medincell MDCLF +393.00% 77 Other Income (Expense) is $-6.26 Mil as of Mar. 2026. GuruFocus rates MDCLF with a GF Score™ of 77/100 and a GF Value™ of $27.51. The stock has 5 warning signs investors should review.

Medincell's other income expense for the Medincell's pretax income for the six months ended in Mar. 2026 was $-5.19 Mil. Its other income expense for the trailing twelve months (TTM) ended in Mar. 2026 was $-6.26 Mil.

Medincell  (OTCPK:MDCLF) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.

Medincell Other Income (Expense) Historical Data

* Premium members only.

The historical data trend for Medincell's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medincell Other Income (Expense) Chart

Medincell Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Income (Expense)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.94 1.29 0.74 1.26 -6.24

Medincell Semi-Annual Data
Mar16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Other Income (Expense) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.64 -0.97 2.21 -1.07 -5.19
MDCLF
77GF Score
Medincell SA MDCLF
Other Income (Expense) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medincell Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Other Income (Expense) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-6.26 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Income (Expense) →
What does a Other Income (Expense) of $-6.26 Mil mean?
Medincell (MDCLF) has a Other Income (Expense) of $-6.26 Mil as of Mar. 2026. Other income and expenses that a company records on the income statement. View historical data on Medincell and its competitors.
Is Medincell's Other Income (Expense) too high?
Medincell's current Other Income (Expense) is $-6.26 Mil. Overall, Medincell has a GF Score™ of 77/100, reflecting its overall financial health beyond just this single metric.
How does Medincell's Other Income (Expense) compare to VRTX and REGN?
Medincell's Other Income (Expense) of $-6.26 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Income (Expense) for a Biotechnology company?
A good Other Income (Expense) depends on the Biotechnology industry context. However, Other Income (Expense) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Income (Expense) mean?
A high Other Income (Expense) can signal that a stock is expensive relative to its fundamentals. Other income and expenses that a company records on the income statement. View historical data on Medincell and its competitors. Medincell's current Other Income (Expense) is $-6.26 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medincell stock overvalued right now?
Medincell (MDCLF) has a current Other Income (Expense) of $-6.26 Mil. The stock's GF Value™ is $27.51, compared to a current price of $34.39 — trading 25% above its estimated fair value. The current Other Income (Expense) is $-6.26 Mil. Medincell's overall GF Score™ is 77/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Income (Expense) calculated?
Other Income (Expense) is calculated from a company's financial statements. For Medincell (MDCLF), the current Other Income (Expense) is $-6.26 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medincell (MDCLF) Overvalued in 2026?

Based on GuruFocus' analysis, Medincell stock appears to be overvalued. The current stock price of $34.39 is trading 25% above its estimated GF Value™ of $27.51.

Key valuation signals for MDCLF:

  • Other Income (Expense): $-6.26 Mil
  • GF Value™: $27.51 vs. price of $34.39 (25% above fair value)
  • GF Score™: 77/100 with 5 warning signs

No single metric tells the full story. See the MDCLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medincell Business Description

Address 3 rue des Freres Lumiere, Jacou, FRA, 34830
Medincell SA is a technology-based pharmaceutical firm, aims to optimise the efficiency of medical treatments and make them accessible geographically. The company's product portfolio uses BEPO-patented technology to develop controlled, long-acting injectable medical treatments for a number of therapeutic fields. The firm has a single operating segment: ongoing research and development on processes that use biodegradable polymers to enable the controlled and prolonged release of the active principles of drugs into the human body and animals by means of injection.
77GF Score

Get the complete analysis for MDCLF

Other Income (Expense) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$34.39
Price
$27.51
GF Value